<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460667</url>
  </required_header>
  <id_info>
    <org_study_id>IV APAP LRYGBP Study</org_study_id>
    <nct_id>NCT01460667</nct_id>
  </id_info>
  <brief_title>Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients</brief_title>
  <acronym>IV APAP</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Center Study of IV Acetaminophen for the Treatment of Post-Operative Pain After Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McLaren Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McLaren Regional Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopic Roux-en-Y gastric bypass (LRYGBP) is a common type of surgery in which length of
      stay and morbidity is intimately associated with post-operative nausea and vomiting (PONV)
      and recovery of bowel function. Medications most commonly used to control for post-operative
      pain are opioid medications, whose well known adverse effects include PONV. Currently, no
      studied adequate alternative to opiates exists for mild-moderate pain relief without the
      aforementioned risks.

      The primary goal for this study is to evaluate the the administration of pre- and
      post-operative IV acetaminophen to determine if there is in an overall decrease in the use of
      opioid analgesics by patient controlled analgesia (PCA) and subsequent decrease in subjective
      PONV leading to sooner return of bowel function, enabling progression to oral intake and
      decrease in post-operative length of stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Opioid use during the post-operative period is a highly effective means of treatment for
      acute pain, however not without its adverse effects including post-operative nausea, vomiting
      (PONV), constipation, urinary retention, sedation and respiratory depression. Such factors
      have been implied in the literature to contribute to prolonged post-operative length of stay,
      delayed return to diet, return of bowel function and increased incidence of ileus.
      Alternatively, non-opioids, such as acetaminophen, aspirin, NSAIDs, and selective
      cyclo-oxygenase-2 inhibitors, can be utilized for acute pain, either alone or in combination
      with opioids. In the bariatric post-surgical population, NSAIDS both oral and IV (Toradol,
      Ibuprofen) are not recommended due to their potential bleeding tendency, anti-inflammatory
      effect, and ulcerogenic effect.

      The LRYGBP may be classified as a surgery type associated with mild to moderate
      post-operative pain. Therefore, the mode of pain relief could directly affect the length of
      stay. The advent of IV acetaminophen serves as a opportunity to investigate in detail the
      efficacy of this non-opioid medication in the management of acute pain in the immediate
      post-operative period without the aforementioned adverse effects as expected from traditional
      opiate medications. A comprehensive approach to this study includes a prospective,
      double-blinded, randomized controlled trial of subjects who will undergo LRYGBP and
      randomized to the study agent (IV acetaminophen) or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference in post-operative opiate consumption (PCA)</measure>
    <time_frame>hourly, 30 hours from first dose of study agent</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>post-operative subjective pain intensity</measure>
    <time_frame>every 2 hours, 30 hours from first dose of study agent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-operative nausea and vomiting (PONV)</measure>
    <time_frame>every 2 hours, 30 hours from first dose of study agent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first post-operative drug administration</measure>
    <time_frame>up to 30 hours from first dose of study agent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to return to flatus</measure>
    <time_frame>up to 30 hours from first dose of study agent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acceptance of rescue medication</measure>
    <time_frame>up to 30 hours from first dose of study agent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first request for rescue medication</measure>
    <time_frame>up to 30 hours from first dose of study agent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>readiness for discharge</measure>
    <time_frame>up to 72 hours from the first dose of study agent</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>IV acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IV 0.9% normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV acetaminophen</intervention_name>
    <description>IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours</description>
    <arm_group_label>IV acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV normal saline</intervention_name>
    <description>0.9% normal saline IV, every 6 hours over 30 hours.</description>
    <arm_group_label>IV 0.9% normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who are scheduled to undergo laparoscopic Roux-en-Y gastric bypass surgery
             (LRYGBP) under general anesthesia.

          -  age 18 to 65 years

          -  BMI &gt;35

          -  ASA scores 1,2, or 3

          -  a negative pregnancy test for female subjects of childbearing age

          -  ability to read, understand and provide informed consent to the study procedures

          -  ability to read and understand the use of pain and nausea scales (VAS)

        Exclusion Criteria:

          -  known hypersensitivity to acetaminophen or opioids

          -  use of opioid or schedule II medications prior to commencement of the study &gt;7 days

          -  those with chronic pain conditions or significant medical disease requiring pain
             control

          -  abnormal liver function (aspartate aminotransferase/alanine aminotransferase/bilirubin
             &gt; 3X upper limit of normal range, active hepatic disease, clinically significant liver
             disease, cirrhosis or hepatitis)

          -  known or suspected alcohol, drug or opiate abuse or dependence; or participation in
             other clinical study within 30 days of surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Lee, B.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>McLaren Regional Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Lee, B.Sc.</last_name>
    <phone>517-505-4640</phone>
    <email>leechr28@msu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>McLaren Regional Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Lee, B.Sc.</last_name>
      <phone>517-505-4640</phone>
      <email>leechr28@msu.edu</email>
    </contact>
    <investigator>
      <last_name>Christina Lee, B.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Kia, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nguyen NT, Ho HS, Palmer LS, Wolfe BM. A comparison study of laparoscopic versus open gastric bypass for morbid obesity. J Am Coll Surg. 2000 Aug;191(2):149-55; discussion 155-7.</citation>
    <PMID>10945358</PMID>
  </reference>
  <results_reference>
    <citation>Walder B, Schafer M, Henzi I, Tram√®r MR. Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain. A quantitative systematic review. Acta Anaesthesiol Scand. 2001 Aug;45(7):795-804.</citation>
    <PMID>11472277</PMID>
  </results_reference>
  <results_reference>
    <citation>Macario A, Royal MA. A literature review of randomized clinical trials of intravenous acetaminophen (paracetamol) for acute postoperative pain. Pain Pract. 2011 May-Jun;11(3):290-6. doi: 10.1111/j.1533-2500.2010.00426.x. Epub 2010 Nov 28. Review.</citation>
    <PMID>21114616</PMID>
  </results_reference>
  <results_reference>
    <citation>Wininger SJ, Miller H, Minkowitz HS, Royal MA, Ang RY, Breitmeyer JB, Singla NK. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery. Clin Ther. 2010 Dec;32(14):2348-69. doi: 10.1016/j.clinthera.2010.12.011.</citation>
    <PMID>21353105</PMID>
  </results_reference>
  <results_reference>
    <citation>Madan AK, Ternovits CA, Speck KE, Tichansky DS. Inpatient pain medication requirements after laparoscopic gastric bypass. Obes Surg. 2005 Jun-Jul;15(6):778-81.</citation>
    <PMID>15978146</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>October 26, 2011</last_update_submitted>
  <last_update_submitted_qc>October 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McLaren Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Christina Lee</investigator_full_name>
    <investigator_title>Study Coordinator, McLaren Regional Medical Center</investigator_title>
  </responsible_party>
  <keyword>Laparoscopic Roux-en-Y Gastric Bypass</keyword>
  <keyword>Post-Operative Pain</keyword>
  <keyword>IV Acetaminophen</keyword>
  <keyword>Post-Operative Nausea and Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 15, 2017</submitted>
    <returned>May 23, 2017</returned>
    <submitted>August 8, 2017</submitted>
    <returned>September 8, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

